Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma

Inclusion Criteria: * Age: 6-17 year olds with documented clinician-diagnosed asthma * Evidence of recent uncontrolled asthma (must meet at least one of the following). This convention for defining poorly-controlled asthma has been successfully used in a large pediatric trial. * ACQ \> 1.2 * Use of short-acting beta-agonist for asthma symptoms twice/week or more on average over the past month * Nocturnal awakenings with asthma symptoms more than once per week on average over the last month * Two or more emergency department visits, unscheduled provider visits, prednisone courses or hospitalizations for asthma in the past 12 months * Currently on stable dose of daily inhaled corticosteroid medication (ICS) for asthma control equivalent to 88mcg of fluticasone or greater for at least 6 weeks from the time of enrollment. Participant must be on National Asthma Education and Prevention Program (NAEPP) controller step 2, 3 or 4. * Currently with mild GERD symptoms reported at V1 defined by a score on the Pediatric GERD Symptom Assessment Score greater than 15 and less than 80. GSAS ranges from 0 to \>440. Exclusion Criteria: * Taking daily CYP2C19 substrates, inducers or inhibitors medication * Past or current history of moderate-severe GERD or related disorders (erosive esophagitis, peptic ulcer disease, eosinophilic esophagitis) which in the opinion of the pediatric gastroenterology safety specialist/study physician requires treatment with acid-blocking agents; * Dail…